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Chelation therapyAbstract Background: Limited data are available about renal involvement in thalassemia
patients. Renal dysfunction in these patients seems to be multifactorial attributed mainly to long
standing anemia, chronic hypoxia, iron overload and toxicity of iron chelators.
Objective: To assess the frequency of subclinical glomerular and tubular dysfunctions in children
and adolescents with b-thalassemia major and intermedia, and to correlate these findings with the
degree of iron overload and type of chelation therapy.
Methods: The study included 40 thalassemia major and 20 thalassemia intermedia pediatric
patients recruited from the Pediatric hematology clinic, Ain Shams University. Serum sodium,
potassium, phosphorous and creatinine, and urinary sodium, potassium, phosphorous, protein/cre-
atinine ratio and urinary b2 microglobulin were measured. Fractional excretion of sodium and
potassium was calculated.
Results: The mean level of serum creatinine in all patients was within the normal range and com-
parable in both TM and TI groups (0.17 ± 0.06 and 0.18 ± 0.07 mg/dl, respectively, P> 0.05).
The mean eGFR was higher than normal range in both TM and TI groups (552.65 ± 231.73
and 472.15 ± 272.99 ml/min, respectively). Mean level of urinary b2 microglobulin was within
the normal range (0.13 ± 0.05 and 0.10 ± 0.03 lg/ml) in TM and TI patients, however, it was sig-
nificantly higher in TM patients (P = 0.009). Urinary b2 microglobulin was positively correlated toetion of
tyl-b-d-
370 A.A.M. Adly et al.both transfusion index and serum ferritin level (P < 0.05). Tubular reabsorption of phosphorus
(TRP) was significantly higher among TM patients (P = 0.037). The mean height and height per-
centile were lower in the poorly chelated group (serum ferritin P2500 ng/ml) than the well chelated
group. In addition, the mean serum sodium and urinary protein/creatinine ratio were significantly
higher in the poorly chelated group (P < 0.05).
Conclusion: Subclinical renal affection can start earlier in TM patients compared to TI. Poor
chelation is associated with early signs of renal affection. Periodic renal assessment of those patients
is mandatory as they may be affected by hidden renal dysfunction.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
b-Thalassemias are a group of hereditary blood disorders
characterized by anomalies in the synthesis of the b chains of
hemoglobin (Hb) resulting in variable phenotypes ranging from
severe anemia to clinically asymptomatic individuals [1].
b-Thalassemia intermedia (b-TI) encompasses a wide clinical
spectrum of the b-thalassemia (b-thal) phenotype. Some b-TI
patients are asymptomatic until adult life, whereas others are
symptomatic from as young as 2 years of age [2]. The severity
of b-TI depends on the degree of imbalance between a and
non-a chains as well as other genetic and environmental factors
that modify the natural history of the disease [3]. b-Thalassemia
major (b-TM) is an inherited Hb disorder characterized by
chronic anemia and iron overload due to transfusion therapy
and gastrointestinal absorption. Iron overload causes most of
the associated mortality and morbidity [1,4]. A number of clin-
ical complications are commonly associated with b-TI, affect-
ing the lives of patients. Prevention of these complications is
ideal since they may be difficult to manage [5,6]. The cost of
providing lifelong medical care to patients with thalassemia
according to the standards adopted in the developed countries
is extremely high. The burden of thalassemia imposed on the
health systems of developing countries is unbearable [7].
With increased duration of survival of children with
b-thalassemia major, the effects of iron overload in the liver,
pancreas, and heart become more severe, however renal
involvement has received little attention [8]. Renal dysfunction
may occur in b-thalassemia major patients showing no clinical
symptoms and before the manifestations of any other compli-
cations [9]. Renal dysfunction in these patients is not known
well and seems to be multifactorial; attributed mainly to
long-standing anemia, chronic hypoxia, iron overload and
toxicity of iron chelators [10].
1.1. Objective
This study aimed to investigate the frequency of subclinical
glomerular and tubular dysfunctions in children and adoles-
cents with b-thalassemia major and b-thalassemia intermedia,
and to correlate these findings with the degree of iron overload
and type of chelation therapy.
2. Patients and methods
This cross sectional study included 60 patients recruited from
the regular attendants of the Pediatric Hematology Clinic,
Pediatric Hospital, Ain Shams University. Patients weredivided into two groups; Group 1 consisted of 40 patients with
b thalassemia major (18 males and 22 females) with age
ranging from 2.5 to 18 years and with a mean age of
10.78 ± 4.03 years, and Group 2 consisted of 20 patients with
b thalassemia intermedia (11 males and 9 females) with age
ranging from 2.5 to 15 years and with a mean age of
8.78 ± 3.45 years. Group 1 patients were further subdivided
into 2 groups according to the serum ferritin level: Well che-
lated group (with serum ferritin <2500 ng/ml) that included
30 patients, 14 males and 16 females, with age ranging from
3 to 18 years and mean age of 11.35 ± 4.25 years. Poorly che-
lated group (with serum ferritin P2500 ng/ml) that included 10
patients, 4 males and 6 females with age ranging from 2.5 to
12 years and a mean age of 9.1 ± 2.8 years. The procedures
applied in this study were approved by the parents of children
as well as approved by the Ethics Committee of Human Exper-
imentation of Ain Shams University, and are in accordance
with the Helsinki Declaration of 1975.2.1. Diagnostic criteria of thalassemia patients
Diagnosis of each type of thalassemia was based on age at pre-
sentation, markers of chronic hemolysis as well as qualitative
and quantitative analysis of Hb. The studied b-TI patients
had the following criteria at the time of initial diagnosis; age
at presentation was more than 2 years, mean Hb level of
8–10 g/dl, HbF < 50% and HbA2 > 4%. The criteria of
b-TM patients at the time of initial diagnosis were: age at pre-
sentation was less than 2 years, mean Hb level of 6–7 g/dl,
HbF > 50% and HbA2 < 4% [11]. Exclusion criteria for
patients under this study included other hemoglobinopathies
(thalassemia minor or sickle-thalassemia), any associated
hemolytic disorder (e.g., glucose 6-phosphate dehydrogenase
deficiency), those with urinary tract infection at time of
sampling and patients with serum creatinine above the upper
normal limit for age.
The main indications for splenectomy in the studied thalas-
semia patients were hypersplenism, splenic pain, leucopenia
and thrombocytopenia, growth retardation, severe exercise
intolerance, increased transfusion demand or symptomatic
splenomegaly [12]. For transfusion status, transfusion therapy
was initiated in b-TI patients mainly for failure to thrive in
childhood, bone deformities, progressive splenic enlargement,
persistent worsening anemia, or development of complications
during the course of the disease. b-Thalassemia major patients
were transfused on regular interval transfusion protocols based
on Hb level (once every 2–5 weeks for a pre transfusion Hb of
<7.0 g/dl). Iron chelation therapy was administered for at
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chelated.3. Methods
All the included patients were subjected to full medical history
taking including age at examination, age at first transfusion,
type of chelator, duration of chelation, compliance to chela-
tion therapy, transfusion index, mean pretransfusion hemoglo-
bin, serum ferritin, platelet count, liver functions, presence or
absence of hepatitis and symptoms suggestive of diabetes mel-
litus. A thorough clinical examination was performed for all
patients with stress on anthropometric measures, pubertal
stage by Tanner’s classification, clinical evidence of complica-
tions of iron overload, and skin hemosiderosis.
3.1. Sample collection
Peripheral blood samples were collected on ethylene diamine
tetra-acetic acid (EDTA) (1.2 mg/ml) for complete blood
count (CBC) and hemoglobin analysis by high-performance
liquid chromatography (HPLC). For chemical analysis, clotted
samples were obtained, and serum was separated by centrifu-
gation for 15 min.
3.2. Diagnostic testing
Laboratory investigations included CBC using SysmexXT-
1800i (Sysmex, Japan), qualitative and quantitative hemoglo-
bin analysis using HPLC by D-10 (BioRad, Marnes La
Coquette, France), liver and kidney function tests as well as
serum ferritin on Cobas Integra 800 (Roche Diagnostics,
Mannheim, Germany). Serum ferritin level was measured rou-
tinely every 3 months during the study with calculation of the
mean value of the last year prior to the study to know the fer-
ritin trend. Markers of hepatitis virus B and C were assessed by
enzyme-linked immunosorbent assay (ELISA). We assessed
different parameters of kidney function for all patients includ-
ing serum electrolytes (sodium, potassium and phosphorous),
serum creatinine, urinary electrolytes (sodium, potassium and
phosphorous), urinary protein/creatinine ratio, estimated
glomerular filtration rate (eGFR) by Schwartz equation for
children: eGFR (ml/min/1.73 m2) = height (cm) · constant/
serum creatinine (mg/dl), where height was expressed in ‘‘cm’’
and constants are 0.44 (for children <2 years) and 0.55 (for
children P2 years) [13], fractional excretion of sodium
(FENa%), fractional excretion of potassium (FEK%) and uri-
nary b2-microglobulin by ELISA (supplied by ORGENTEC).
For measurement of urinary electrolytes, five milliliters of urine
was divided into two aliquots; one for the immediate assess-
ment of sodium, potassium, phosphorous, creatinine and
protein and the other aliquot was stored at 20 C for the
subsequent assay of b2-microglobulin.
3.3. Statistical method
Statistical analysis was performed using SPSS 17.0 statistical
package. All results were expressed as mean and SD values
for parametric data and median, IQR for non-parametric
quantitative data. Student’s t-test was used for mean values,Mann–Whitney test for non-parametric quantitative data
and Chi-square test for comparing categorical variables. Pear-
son correlation and Spearman’s rho were used for correlation
in parametric and non-parametric data respectively. P value
<0.05 was considered significant.
4. Results
4.1. Clinical and demographic data of the studied patients
Our study included 60 thalassemic patients, 40 (66.7%)
patients with TM and 20 (33.3%) patients with thalassemia
intermedia. The demographic characteristics of our patients
are shown in Table 1. Age at first transfusion was significantly
lower in TM patients compared to TI patients (P < 0.001). As
regards weight, height and BMI percentiles, they were compa-
rable among TM and TI patients.
50% of TI patients were not on iron chelation therapy com-
pared to only 5% in TM patients (P < 0.0001). Deferiprone
was the most prevalent iron chelator. It was used as a single
chelator by 27.5% of TM patients and 25% of TI patients.
17.5% of TM patients and 15% of TI patients were treated
by deferoxamine only. 25% of TM patients were on combined
deferiprone and deferoxamine chelation therapy compared to
only 10% 0f TI patients. The iron chelator deferasirox was
used by 25% of TM patients while none of TI patients used
deferasirox (Table 2). Patients with TM used a significantly
higher dose of deferoxamine (P = 0.04) and were on longer
chelation duration compared to TI patients (P = 0.0001).
Compliance to chelation was higher in TM patients; 30
patients (75%), compared to 11 patients (55%) with TI.
Among our 60 patients, there were 22 patients in the puber-
tal stage; 17 (77%) of them showed delayed puberty for age, 12
patients with TM (30%) and 5 patients with TI (25%). 53% of
those patients were males and 47% were females. Also, 15
(25%) of all our patients were splenectomized; 14 (35%)
belonged to the TM group and only one (5%) to the TI group
(P= 0.91) as shown in Table 3. In addition, 17 (42.5%) of our
TM patients had skin hemosiderosis compared to only 2 (10%)
TI patients (P = 0.03) (see Table 4).
In the present study, the mean height as well as the height
percentile were lower in the poorly chelated group (serum fer-
ritin P2500 ng/ml) than the well chelated group (serum ferritin
<2500). We found also that splenectomy cases were more pre-
valent in the poorly chelated group; 4 cases out of 10 (40%)
compared to 10 cases out of 30 in the well chelated group
(33.3%), (Results not shown). In addition, the mean serum
sodium and urinary protein/creatinine ratio were significantly
higher in the poorly chelated group than in the well chelated
group (P < 0.05) as shown in Table 5.
4.2. Laboratory parameters of the studied patients
Laboratory serum and urine parameters of both thalassemia
major and intermedia are shown in Table 4. The mean level
of serum creatinine in all our cases was within the normal
range and comparable in both TM and TI groups
(P> 0.05). The mean estimated GFR (done by Schwartz
equation) among our studied patients was higher than the nor-
mal range in both TM and TI groups indicating glomerular
hyperfiltration. Also, the mean urinary protein/creatinine ratio
Table 1 Comparison of demographic data among TM and TI patients.
TM N = (40 cases) TI (N= 20 cases) Test P
Gender Xb/zc/td
Male N (%) 18 (45%) 11 (55%) 0.53b 0.47
Female N(%) 22 (55%) 9 (45%)
Mean ± SD Mean ± SD Test P
Age (years) 10.78 ± 4.03 8.78 ± 3.46 1.91d 0.06
Age at 1st transfusion (months) 14.60 ± 9.23 45.95 ± 9.23 4.45c 0.0001a
Weight (kg) 30.56 ± 11.49 26.43 ± 10.84 1.49c 0.14
Height (cm) 130.93 ± 17.98 122.8 ± 21.64 2.30d 0.058
BMI (kg/m2) 17.22 ± 2.65 18.37 ± 4.26 0.68c 0.49
Weight percentile 19.62b 0.02a
Below 10th 17 (2.5%) 12 (60%)
Above 10th 23 (97.5.5%) 8 (40%)
Height percentile 3.50 0.94
Below 10th 23 (57.5%) 15 (75%)
Above 10th 17 (42.5%) 5 (25%)
BMI percentile 11.06b 0.35
Below 10th 13 (32.5%) 3 (15%)
Above 10th 27 (67.5%) 17 (85%)
TM: thalassemia major, TI: thalassemia intermedia, BMI: body mass index.
a Significant p< 0.05.
b Chi square test (Fisher exact).
c Mann–Whitney test.
d Independent t-test.
Table 2 Comparison of chelation use and compliance among thalassemia major and thalassemia intermedia patients.
TM (N= 40 cases) TI (N= 20 cases) Test P
Chelation type N (%) Xb/zc/td
1-No chelator 2 (5%) 10 (50%) 20.081b 0.0001a
2-deferroxamine 7 (17.5%) 3 (15%)
3-deferiprone 11 (27.5%) 5 (25%)
4-deferasirox 10 (25%) 0 (0%)
2 + 3 10 (25%) 2 (10%)
Compliance
Non-compliant 10 (25%) 9 (45%) 2.465b 0.116
Compliant 30 (75%) 11 (55%)
Dose (mg/kg/d) Mean ± SD Mean ± SD
Deferoxamine 31.76 ± 7.28 24 ± 5.48
2.195d 0.04a
Deferiprone dose 88.09 ± 12.79 82.14 ± 12.2 1.074c 0.283
Duration of chelation (years) 5.41 ± 3.83 1.90 ± 2.97 3.956c 0.0001a
TM: thalassemia major, TI: thalassemia intermedia.
a Significant p< 0.05.
b Chi square test (Fisher exact).
c Mann–Whitney test.
d Independent t-test.
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11 of all our studied patients (18.3%); 8 TM patients (20%)
and 3 TI (15%) patients had a protein/creatinine ratio higher
than normal. The mean level of urinary b2 microglobulin in
our patients was within the normal range, where only 2 TM
patients (3.3%) had slightly higher levels than normal. Mean-
while, all TI patients included in the study showed normal uri-
nary b2 microglobulin levels. However, the mean urinary b2
microglobulin was significantly lower in TI patients
(P = 0.009). Normal mean levels of fractional excretion ofsodium (FENa%) and fractional excretion of potassium
(FEK%) were found among TM and TI patients with no sig-
nificant difference between the two groups (P > 0.05) (see
Table 6).
The mean serum potassium and serum sodium in all our
cases were within the normal range but there was a significant
difference between TM and TI groups, where the mean serum
potassium was higher in TM patients than in TI patients
(P = 0.04) and the mean serum sodium was higher among
TI patients than TM patients (P= 0.01).
Table 4 Comparison of laboratory parameters among thalassemia major and thalassemia intermedia patients.
TM N= 40 TI N= 20 Test P Reference ranges
Mean ± SD Mean ± SD z^/tb
Serum K (mmol/L) 4.25 ± 0.42 4 ± 0.38 2.099b 0.040a 3.5–5.3 mmol/L
Serum Na (mmol/L) 132 ± 4.56 134.95 ± 2.91 2.523c 0.012a 135–148 mmol/L
Serum Ph (mg/dl) 6.99 ± 2.10 5.46 ± 0.93 3.505c 0.000a Child: 4–7 mg/dl
Adult: 2.5–4.5 mg/dl
Serum creatinine (mg/dl) 0.17 ± 0.06 0.18 ± 0.07 0.852c 0.394 Child: 0.3–0.7 mg/dl
Adolescent: 0.5–1 mg/dl
Urinary b2 microglobulin (lg/ml) 0.13 ± 0.05 0.10 ± 0.03 2.606c 0.009a 0–0.3 lg/ml
Urinary Na (meq/L) 121.86 ± 81.22 117.78 ± 64.04 0.369c 0.712
Urinary K (meq/L) 71.86 ± 38.25 55.24 ± 33.43 1.560c 0.119
Urinary Ph (meq/L) 25.28 ± 13.30 24.72 ± 9.24 0.078c 0.937
Urinary creat (mg/dl) 88.88 ± 50.62 76.77 ± 31.42 0.572c 0.567
Urinary protein/creat ratio 0.27 ± 0.29 0.49 ± 1.35 0.704c 0.481 Up to 0.2
FENa (%) 0.20 ± 0.20 0.28 ± 0.22 1.216c 0.224 <1: prerenal failure
>2: acute tubular necrosis
FEK (%) 3.51 ± 2.49 3.10 ± 1.60 0.298c 0.766 <10: renal cause of hyperkalemia
>10: extrarenal cause of hyperkalemia
TRP 0.99 ± 0.005 0.98 ± 0.01 2.083c 0.037a Normal >80%
i.e. >.80
eGFR 552.65 ± 231.73 472.15 ± 272.99 1.709c 0.087 Male: 94–140 ml/min
Female: 72–110 ml/min
TM: thalassemia major, TI: thalassemia intermedia, Na: sodium, K: potassium, ph: phosphorus, creat: creatinine, Ptn: protein, FENa: frac-
tional excretion of sodium, FEK: fractional excretion of potassium, TRP: tubular reabsorption of phosphorus, eGFR: estimated glomerular
filtration rate.
a Significant p < 0.05.
b Independent t-test.
c Mann–Whitney test.
Table 3 Comparison of different complications among thalassemia major and thalassemia intermedia patients.
TM TI Test P
(n= 40) N (%) (n = 20) N (%) Xb
Skin hemosiderosis 17 (42.5%) 2 (10%) 4.97 0.03a
Splenectomy 14 (35%) 1 (5%) 6.47 0.91
Liver functions(elevated liver enzymes >3 times normal IU/L) 10 (25%) 0 (0%) 5.29 0.02a
Hepatitis C +ve 4 (10%) 0 (0%) 2.14 0.14
Puberty 0.17 0.68
Not includedc 24 (60%) 14 (70%)
Normal 4 (10%) 1 (5%)
Delayed 12 (30%) 5 (25%)
TM: thalassemia major, TI: thalassemia intermedia.
a Significant p < 0.05.
b Fisher exact test.
c Prepubertal.
Table 5 Number and percentage of patients with renal dysfunction in both groups.
Thalassemia major N= 40 Thalassemia intermedia N= 20
Abnormal GFR n(%) 40 (100%) 20 (100%)
Abnormal ACR n(%) 8 (20%) 3 (15%)
Abnormal Na – –
Abnormal K – –
Abnormal phosphorous 18 (30%) 2 (3.3%)
Abnormal b2 microglobulin 2 (3.3%) –
GFR: glomerular filtration rate, ACR: albumin creatinine ratio, Na: sodium, K: potassium.
Subclinical renal abnormalities in young thalassemia major and intermedia patients 373
Table 6 Comparison of renal functions between well chelated and poorly chelated groups.
Well chelated N= 30 Poorly chelated N= 10 Test tb/zc P
Serum Na 131.22 ± 4.77 134.45 ± 2.82 2.59b 0.02a
Serum K 4.08 ± 0.35 4.31 ± 0.35 1.59b 0.12
Serum Ph 7.29 ± 2.32 6.98 ± 0.83 2.08b 0.06
Serum creatinine 0.17 ± 0.07 0.15 ± 0.05 0.95b 0.36
Urinary Ptn/creat ratio(mg/mmol) 0.23 ± 0.22 0.4 ± 0.42 1.98c 0.048a
Urinary b2 microglobulin 0.12 ± 0.26 0.13 ± 0.05 0.33c 0.74
Urinary Na 113.94 ± 78.5 144.9 ± 89.06 1.09c 0.27
Urinary K 70.35 ± 40.07 76.40 ± 33.68 0.55c 0.59
Urinary P 24.21 ± 13.39 28.5 ± 13.17 1.17c 0.24
Urinary creat 85.44 ± 50.85 99.2 ± 51.15 0.91c 0.37
FENa 0.22 ± 0.22 0.16 ± 0.09 0.28c 0.78
FEK 3.74 ± 2.75 2.83 ± 1.35 0.59c 0.55
TRP 0.99 ± 0.01 0.99 ± 0.003 0.29c 0.77
eGFR 558.58 ± 239.07 534.86 ± 219.23 0.53c 0.60
S: serum, U: urinary, Na: sodium, K: potassium, P: phosphorus, creat: creatinine, Ptn: protein, FENa: fractional excretion of sodium, FEK:
fractional excretion of potassium, TRP: tubular reabsorption of phosphorus, eGFR: estimated glomerular filtration rate.
a Significant p< 0.05.
b Independent t-test.
c Mann–Whitney test.
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significantly and positively correlated to serum ferritin level as
shown in Fig. 1 and transfusion index, (r= 0.27, P = 0.04
and r= 0.32, P= 0.013, respectively). The tubular reabsorp-
tion of P (TRP) was significantly higher among TM patients
compared to TI patients (P = 0.037). A significant negative
correlation was found between duration of chelation and
TRP in TI patients (P = 0.04). Our study showed that the
mean serum phosphorus level in all the study patients wasFigure 1 Shows a positive correlation between serum ferritin andwithin the normal range, but 20 (33.3%) of our cases; 18
(30%) TM patients and 2 (3.3%) TI patients had high serum
phosphorus levels.
On the other hand, the mean serum ferritin level was signif-
icantly higher in TM than in TI patients (P = 0.001). There
was a significant positive correlation between serum ferritin
and transfusion index (P = 0.001). Also, a significant negative
correlation existed between serum ferritin and mean pretrans-
fusion hemoglobin (P = 0.03).urinary b2 microglobulin in all the study patients (P = 0.04).
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Several investigations about renal involvement in adult beta
TM patients [14–16] were reported but there is a dearth of
pediatric data. This study was designed to investigate the fre-
quency of subclinical glomerular and tubular dysfunctions in
children and adolescents with beta thalassemia major and
intermedia.
22 of our patients were in the pubertal stage, of which 17
(77%) showed delayed puberty for age, 53% were males and
47% were females. Our results are in agreement with a previ-
ous study done by El-Beshlawy and Mokhtar on Egyptian
b-thalassemia patients where failure of puberty was observed
among 71.4% of males and 33.3% of females [17].
Our study showed a higher prevalence of splenectomy and
hemosiderosis in thalassemia major patients compared to
thalassemia intermedia, (P = 0.91 and P = 0.03), respectively.
This might be due to higher serum ferritin levels among our
TM patients when compared to TI patients. In contrast,
Smolkin et al. mentioned that serum ferritin level does not
sufficiently reflect the degree of hemosiderosis [18].
The mean level of serum creatinine in our patients was
within the normal range. This is in consistence with other stud-
ies [7–10], where serum creatinine level was within the normal
range among both TM and TI patients [19,20]. Other studies
[21,22] reported that serum creatinine was within the normal
range among TM patients; but it was higher when compared
to that of the normal population (control group). In our study,
serum creatinine level was comparable between TM and TI
patients. Ali et al. [23] found that serum creatinine was signif-
icantly higher in TM than TI patients. Likewise, El-Alfyet
et al. [24] reported that patients with thalassemia major had
significantly higher serum creatinine and blood urea nitrogen
values, possibly due to higher iron deposition in their kidneys.
Our patients were on different types of chelation therapy and
all cases proved to have normal serum creatinine. Previous
studies reported normal serum creatinine in patients who
received subcutaneous DFO treatment [8,25]. Other studies
showed nephrotoxic effects of DFO in beta thalassemic
patients [15]. The mean GFR in our study (done by Schwartz
equation) was higher than the normal range in both TM and
TI groups indicating glomerular hyperfiltration. This was in
agreement with other studies [26], which found that a total
of 24 thalassemia intermedia patients (48%) had evidence of
glomerular hyperfiltration (>149 ml/min/1.73 m2) for males
and females. Other studies [9,18] however, found that the mean
GFR (evaluated by Schwartz formula) was within the normal
reference range (107.5 ± 1.27 ml/min/1.73 m2), and was com-
parable in TM and TI patients. Glomerular hyperfiltration
may be accounted for by the underlying anemia. There is
evidence that anemia may reduce systemic vascular resistance,
leading to a hyperdynamic circulation that can increase the
renal plasma flow and GFR. Hyperfiltration can lead to
stretching of the glomerular capillary wall and epithelial injury
leading to progressive decline of GFR. Also when iron
overload becomes severe it can cause damage of the tubular
cells. In turn, the injured cells reverse into the interstitium
cytokines and growth factors causing scarring and glomerular
sclerosis [27].
As regards urinary protein/creatinine (U pr/Cr) ratio, the
mean level of albumin/creatinine (A/C) ratio among ourpatients was 0.35 ± 0.81 mg/mmol which was higher than
the normal range. Mohkam et al. [9] reported that 89.3% of
their patients had abnormal U pr/Cr ratio. Also, Ziyadeh
et al. [26] found that 30 of their patients (60%) had abnormal
U pr/Cr ratio and it was positively correlated with serum
ferritin (P = 0.04). In our study, unlike other studies there
was no significant correlation between U pr/Cr ratio and
serum ferritin (P = 0.9). Also, Ali and Mahmoud [28] found
statistically higher ratios of A/C in urine of thalassemic chil-
dren compared to the control group. This albuminuria was
attributed mainly to the destruction of the glomerular filtration
membrane which may be due to massive iron deposition in the
tissues, resulting in an increase of free radical production via
the Fenton reaction, leading to cell death by binding cell
proteins and disturbing their production [29,30]. In addition,
albuminuria could result from prolonged hyperfiltration, pros-
taglandin secretion and chronic anemia [31].
Urinary b2 microglobulin (b2MG) is a low molecular
weight protein (11.8 kDa) which, under normal circumstances,
is freely filtered at the glomerulus but almost totally
reabsorbed and degraded by renal tubules [32]. Elevation of
urinary b2MG is a sensitive and reliable early marker of tubu-
lar dysfunction [33,34]. In our study, the mean level of urinary
b2 microglobulin was within the normal range
(0.12 ± 0.05 lg/ml). Only 2 patients (3.3%) among TM group
had slightly higher levels than normal while all TI patients
included in our study showed normal urinary b2 microglobulin
levels (P = 0.01). Similar results were reported in other studies
where Mula-Abed et al. [35] reported that only 3(10%) of their
patients had high urinary b2 microglobulin level. Meanwhile,
earlier studies [15] reported that 13 of 19 TM patients had
renal tubular damage, among them, 11 patients (85%) had
high level of urinary b2 microglobulin. This marked difference
among the compared studies may be due to improvement of
thalassemic patients’ care which probably led to decreased rate
of proximal tubular damage.
Regarding tubular reabsorption of phosphorus (TRP), we
found a significant difference between TM and TI patients
included in our study. However, both were within the normal
range. Similar findings were found by other studies [18,35],
where no patients had TRP < 85%, which excluded the possi-
bility of a renal tubular phosphate leak.
There was no affection in the mean fractional excretion of
sodium (FENa)% and mean fractional excretion of potassium
(FEK)% among our studied patients and no difference
between both TM and TI patients groups denoting that there
was no renal tubular affection regarding these mentioned
parameters. This is in agreement with other studies [18]. How-
ever, Mohkam et al. [9], reported abnormal levels of FENa(%)
and FEK(%) in 29.1% and 7.8% respectively among their
studied patients. Mula-Abed et al. [35], found that almost all
their studied patients had normal FENa(%) with only two
patients (6.7%) showing slightly raised FENa > 1% indicat-
ing the possibility of developing prerenal failure which can
be explained by prolonged anemia and hypovolemia which
are constant findings in thalassemic patients.
The mean serum sodium and potassium among our cases
were within the normal range. Similar findings were previously
reported by other studies [8,14]. However, in our study there
were significant differences between TM and TI in mean serum
potassium (P = 0.04) and in mean serum sodium levels
(P= 0.01). On the other hand, Al-Samarrai et al. [36] reported
376 A.A.M. Adly et al.higher levels of serum Na and K in thalassemic patients than
the control group. An increase in serum Na level in TM may
be due to renal damage resulting from iron overload in such
patients, whereas, the increase in serum K level occurs in
patients with RBCs hemolysis which may occur in stored
blood that is transfused to patients since K tends to leak from
RBCs to the plasma of stored blood [36].
Regarding serum ferritin in our study, the mean levels were
2044.88 ± 782.65 and 874.83 ± 379.88 ng/ml in TM and TI
respectively, which showed a highly significant difference
between the two groups (P = 0.001). This was similar to the
study done by Alfery et al. [37] in which TM patients had a sig-
nificantly higher mean serum ferritin level compared to TI
patients; (P < 0.05). We also found a significant positive cor-
relation between serum ferritin and transfusion index
(P = 0.001) and a significant negative correlation between
serum ferritin and mean pretransfusion hemoglobin
(P = 0.03). This was in accordance with other studies [38],
which found that increased number of blood transfusions were
associated with increase in the serum ferritin level.
In our study, we further subdivided our TM patients
according to the serum ferritin; into well chelated and poorly
chelated groups where the mean serum ferritin level was signif-
icantly different between the two groups (P = 0.001). This was
in agreement with other studies which reported similar results
when they divided their patients according to their serum fer-
ritin levels [38].
In our study, the mean height and height percentile in the
poorly chelated group were lower than the well chelated group
but the difference was not statistically significant. However,
other studies [38] reported significant short stature for age
among their poorly chelated group (serum ferritin P2500 ng/
ml) when compared to the well chelated group (serum ferritin
<2500 ng/ml) (P< 0.001). Pemde et al. [39], classified their
thalassemic patients into two groups, one with serum ferritin
<2000 ng/ml and the other with serum ferritin >2000 ng/
ml, and they reported that the height of the patients with
serum ferritin >2000 ng/ml was significantly lower than those
with serum ferritin <2000 ng/ml. However, in an earlier study
done in India by Gomber and Dewan [40], no relation between
physical growth and serum ferritin level was found.
Notably, in the present study, we found that cases that
underwent splenectomy were more prevalent among the poorly
chelated group; 4 cases (40%) versus 10 cases (33.3%) among
the well chelated group, while the difference was not statisti-
cally significant. Similar findings were reported by Bashir
and Sadoon [38], where the number of splenectomized cases
among the poorly chelated group (serum ferritin P2500 ng/
ml) was 5 (23.8%) compared to 9 (11.39%) in the well chelated
group (serum ferritin <2500 ng/ml) (P< 0.001).
As regards laboratory parameters of renal function, there
was a significant difference between the mean serum sodium
in the poorly chelated group and the well chelated group
(134.45 ± 2.82 mmol/L vs. 131.22 ± 4.77 mmol/L), (P =
0.01). Also, the mean urinary protein/creatinine ratio in the
poorly chelated group was significantly higher and above the
normal range compared to the well chelated group
(0.4 ± 0.42 mg/mmol vs. 0.23 ± 0.22 mg/mmol), (P = 0.04).
This indicates a correlation between renal function in thalasse-
mic patients and serum ferritin level. Other studies [18] have
found a direct correlation of renal function disturbance tototal amount of transfused iron but not to the actual serum
ferritin level.
6. Conclusion
Subclinical renal affection is more common and could start
earlier in TM patients compared to TI. Poor chelation is an
important risk factor for early renal affection. Periodic renal
assessment of those patients is mandatory as they may be
affected by hidden renal dysfunction.
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